Two Sigma Investments, LP Verve Therapeutics, Inc. Transaction History

Two Sigma Investments, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$2.97 - $11.38 $1.29 Million - $4.93 Million	432,779 Added 114.01%	812,360 $9.12 Million
Q1 2025 May 15, 2025	SELL	$4.57 - $8.63 $871,604 - $1.65 Million	-190,723 Reduced 33.44%	379,581 $1.73 Million
Q4 2024 Feb 14, 2025	BUY	$4.5 - $7.19 $630,135 - $1.01 Million	140,030 Added 32.54%	570,304 $3.22 Million
Q3 2024 Nov 14, 2024	SELL	$4.4 - $7.86 $779,675 - $1.39 Million	-177,199 Reduced 29.17%	430,274 $2.08 Million
Q2 2024 Aug 14, 2024	BUY	$4.76 - $12.79 $1.72 Million - $4.63 Million	361,891 Added 147.36%	607,473 $2.96 Million

Q1 2024 May 15, 2024	BUY	$10.81 - $17.96 $1.83 Million - $3.04 Million	169,069 Added 220.97%	245,582 $3.26 Million
Q4 2023 Feb 14, 2024	BUY	$8.84 - $18.7 $676,374 - $1.43 Million	76,513 New	76,513 $1.07 Million
Q1 2023 May 15, 2023	BUY	$14.3 - $24.01 $2.03 Million - $3.4 Million	141,756 New	141,756 $2.04 Million
Q2 2022 Aug 15, 2022	BUY	$11.14 - $23.17 $325,143 - $676,262	29,187 Added 105.77%	56,781 $868,000
Q1 2022 May 16, 2022	BUY	$20.92 - $39.36 $577,266 - $1.09 Million	27,594 New	27,594 $630,000

8.51M

2.9K

37.1K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $667M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.